FoxM1 has been identified as an integrin β1 transcription factor thereby promoting breast cancer progression 27, implying a possibility that USP22 controls breast cancer cell ITGB1 expression through FoxMl stabilization. This evidence concerns the gene ITGB1 and breast carcinoma.